It is a bit of a borderline decision here. The work is very encouraging, but as we don’t have a committed ovarian cancer program (this is under evaluations as part of Pillar 3) it could be considered not price sensitive. If we were still on the 5-Path strategy (ovarian was path 5) it would have been price sensitive.
More importantly I am happy to answer any questions about the work you might have.
Ann: Positive Early Preclinical Ovarian Cancer Results, page-11
-
- There are more pages in this discussion • 75 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
-0.060(4.00%) |
Mkt cap ! $245.4M | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.50 | $1.44 | $57.11K | 38.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2499 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 247 | 1 |
View Market Depth
| Last trade - 16.10pm 31/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |